Bispecific Anti ErbB1 / Anti cMet Antibodies
AssigneeRoche Glycart AG
InventorsBirgit Bossenmaier, Ulrich Brinkmann, Christian Klein, Gerhard Niederfellner, Wolfgang Schaefer, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
Life of this patent
Estimating the term…
Abstract
The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Claims13
A bispecific antibody that specifically binds to human ErbB-1 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-1 and a second antigen-binding site that specifically binds to human c-Met, wherein the bispecific antibody causes an increase in internalization of c-Met on OVCAR-8 cells of no more than 15% when measured after 2 hours of OVCAR-8 cell-antibody incubation as measured by a flow cytometry assay as compared to internalization of c-Met on OVCAR-8 cells in the absence of the bispecific antibody.
A bispecific antibody that specifically binds to human ErbB-1 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-1 and a second antigen-binding site that specifically binds to human c-Met, wherein
- i) the first antigen-binding site comprises in the heavy chain variable domain a CDR3 region with the amino acid sequence of SEQ ID NO:
- 17, a CDR2H region with the amino acid sequence of SEQ ID NO:
- 18, and a CDR1H region with the amino acid sequence of SEQ ID NO:19, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO:
- 20, a CDR2L region with the amino acid sequence of SEQ ID NO:21, and a CDR1L region with the amino acid sequence of SEQ ID NO:58 or a CDR1L region with the amino acid sequence of SEQ ID NO:22;
- and
- the second antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO:
- 30, a CDR2H region with the amino acid sequence of, SEQ ID NO:
- 31, and a CDR1H region with the amino acid sequence of SEQ ID NO:
- 32, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO:
- 33, a CDR2L region with the amino acid sequence of SEQ ID NO:
- 34, and a CDR1L region with the amino acid sequence of SEQ ID NO:
- 35.
- ii) the first antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO:
- 23, a CDR2H region with the amino acid sequence of SEQ ID NO:
- 24, and a CDR1H region with the amino acid sequence of SEQ ID NO:25, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO:
- 26, a CDR2L region with the amino acid sequence of SEQ ID NO:27, and a CDR1L region with the amino acid sequence of SEQ ID NO:28 or a CDR1L region with the amino acid sequence of SEQ ID NO:29;
- and
- the second antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO:
- 30, a CDR2H region with the amino acid sequence of, SEQ ID NO:
- 31, and a CDR1H region with the amino acid sequence of SEQ ID NO:
- 32, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO:
- 33, a CDR2L region with the amino acid sequence of SEQ ID NO:
- 34, and a CDR1L region with the amino acid sequence of SEQ ID NO:
- 35.
Dependencies are inferred from the claim text.